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Objective: While Hungary is often reported to have the highest incidence and mortality
rates of lung cancer, until 2018 no nationwide epidemiology study was conducted to
confirm these trends. The objective of this study was to estimate the occurrence of lung
cancer in Hungary based on a retrospective review of the National Health Insurance Fund
(NHIF) database.
Methods: Our retrospective, longitudinal study included patients aged ≥20 years who
were diagnosed with lung cancer (ICD-10 C34) between 1 Jan 2011 and 31 Dec 2016.
Age-standardized incidence and mortality rates were calculated using both the 1976 and
2013 European Standard Populations (ESP).
Results: Between 2011 and 2016, 6,996 – 7,158 new lung cancer cases were recorded
in the NHIF database annually, and 6,045 – 6,465 all-cause deaths occurred per year.
Age-adjusted incidence rates were 115.7–101.6/100,000 person-years among men
(ESP 1976: 84.7–72.6), showing a mean annual change of − 2.26% (p = 0.008).
Incidence rates among women increased from 48.3 to 50.3/100,000 person-years (ESP
1976: 36.9–38.0), corresponding to a mean annual change of 1.23% (p = 0.028).
Age-standardized mortality rates varied between 103.8 and 97.2/100,000 person-years
(ESP 1976: 72.8–69.7) in men and between 38.3 and 42.7/100,000 person-years (ESP
1976: 27.8–29.3) in women.
Conclusion: Age-standardized incidence and mortality rates of lung cancer in Hungary
were found to be high compared to Western-European countries, but lower than those
reported by previous publications. The incidence of lung cancer decreased in men, while
there was an increase in incidence and mortality among female lung cancer patients.
Keywords: lung cancer, incidence, mortality, epidemiology, European standard population, Hungary
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INTRODUCTION
Lung cancer was the most commonly diagnosed tumor in 2018
and the first cause of cancer death worldwide in both sexes (1, 2).
Monitoring the incidence andmortality of lung cancer is essential
for both the design and evaluation of public health interventions,
as well as for the evaluation of treatment effectiveness.
Despite improving trends, Hungary is still reported to be
among European countries with the highest incidence and
mortality of lung cancer. An article series starting from 1990
published in the European Journal of Cancer (EJC) projected
the incidence of lung cancer to be 109.3/100,000 standardized
person-years (SPYs) among men and 46.5/100,000 SPYs among
women in 2012 (2), and to be 111.6 and 58.7/100,000 SPYs,
respectively in 2018 (3) using the ESP 1976 for standardization.
Results from further epidemiology studies were in line with these
observations regarding the position of Hungary in Europe (4).
Youlden et al. even reported the highest worldwide incidence
of lung cancer for Hungary, with a continuously increasing
incidence among Hungarian women, but a decreasing trend
in incidence among Hungarian men between 1995 and 2015
(5). Similarly to the high incidence of lung cancer in Hungary,
mortality was also reported to be high in the EJC report
series: mortality rates were 96.4/100,000 person-years in men
and 37.7/100,000 person-years in women in 2012 (2). These
publications used WHO GLOBOCAN as a source of Hungarian
lung cancermortality rates which receives regular inputs from the
Hungarian Central Statistician Office (CSO). The CSO reports
annual mortality rates for all cancer types in Hungary including
lung cancer based on death certificates1. Between 2011 and 2016,
33,093 male and 19,296 female deaths were recorded in the
database with lung cancer registered as the cause of death.
While Hungary is often reported to have the highest incidence
and mortality rates of lung cancer, Hungary did not report any
nationwide incidence rates during the last decades, and no exact
clinical data source and explanation were provided to support
the trends mentioned above. Therefore, the main objective of our
study was to explore the incidence, prevalence andmortality rates
of lung cancer in Hungary between 2011 and 2016 based on data
source similar to Western European countries’ national clinical
registries, and to explore trends in both genders.
MATERIALS AND METHODS
Study Design
Our retrospective, longitudinal study was performed using the
database of the National Health Insurance Fund of Hungary
(NHIF). The NHIF database is a nationwide insurance system
covering close to 100% of the Hungarian population, which
collects patient ID and ICD-10 code information about all in-
and out-patient visits, as well as about all prescription of drugs
which are reimbursed in Hungary. The study was approved
by the National Ethical Board for Health Research (10338-
5/2019/EKU).
1http://statinfo.ksh.hu/Statinfo/haDetails.jsp (accessed June 6, 2019).
TABLE 1 | Inclusion, exclusion criteria.
Inclusion criteria
Newly diagnosed lung cancer between 1 Jan. 2011 and 31 Dec. 2016
Two occurrences of the ICD-10 code C34 within more than 30 days but <365
days from diagnosis
One occurrence of the ICD-10C code 34 if a patient died within 60 days after
the first C34 code
Age above 20 years at diagnosis
Exclusion criteria
Cancer-related ICD-10 codes other than C34 within 6 months before or 12
months after diagnosis
Anticancer therapy other than lung cancer treatment protocols within 6 months
before or 12 months after the first lung cancer ICD-10 code
Our analysis included patients with lung cancer (ICD-10:C34)
who were newly diagnosed between 1 Jan. 2011 and 31 Dec. 2016
and were above 20 years of age at the time of diagnosis (Table 1).
To avoid the potential miscoding of lung cancer, we included
patients with a minimum of two occurrences of the ICD-10
code C34 within more than 30 but <365 days. This ensured
that we only included patients who were actually involved in
lung cancer care. One occurrence of C34 was also accepted if a
patient died within 60 days after the first C34 code, when the
repeated occurrence of the ICD code C34 was not applicable.
To avoid the inclusion of patients with lung metastases from a
different primary tumor due to miscoding, we excluded patients
with cancer-related ICD-10 codes other than C34 and those
receiving anticancer therapy other than lung cancer treatment
within 6 months before or 12 months after the first occurrence of
C34. The 3-years period between 2008 and 2010 was considered
as a reference period to detect newly diagnosed lung cancer
patients in 2011. Data on the size of the Hungarian population
for incidence and prevalence calculations by age and sex were
obtained from the Hungarian CSO. The dates and numbers of
deaths among lung cancer patients were also collected from the
NHIF database.
The annual numbers of newly diagnosed lung cancer patients
are presented as crude numbers (n), and as incidence rates per
100,000 persons at risk. The annual number of deceased patients
was also determined. All-cause mortality was expressed as crude
numbers of death and crude all-cause mortality rates per 100,000
person-years in the respective sex- and age-specific group of
the population. We also calculated standardized incidence and
mortality rates. Incidence and mortality data were adjusted for
age using the ESP from 2013 (6) and from 1976 to allow for direct
comparisons with earlier publications. Where crude numbers of
any parameter were recorded below 10, we indicated “<10” as
the Hungarian NHIF data protection laws does not permit the
presentation of case numbers below 10 in a stratum. In these
cases, calculations were run on the exact crude numbers.
Statistical Analysis
Linear regression was applied to estimate the annual change of
the mean age of patients. The outcome was age in years, the
explanatory variable was the year. Poisson regression was used to
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estimate the annual change of the crude incidence and mortality.
The outcome was the number of patients, the offset was the log of
the number of patients at risk (in the case of incidence) and the
mid-year population published by Hungarian Central Statistical
Office (in the case of prevalence), the explanatory variables were
the year, age group, gender, and their paired interactions. The size
of the at-risk population was determined based on the difference
between mid-year population sizes and the number of previously
diagnosed lung cancer patients on 1 January each year. The
same method was used for incidence, prevalence, and mortality
rates. The outcomes were the rates for 100,000 person-years
standardized for the European population (standard ESP 2013).
In all regressionmodelsmentioned above we estimated annual
trends with 95% confidence intervals (95% CI). As data were
not independent (e.g., the same person was in the diseased
population in different years), a block-based bootstrap method
was used for time series with a fixed block size of two.
We also studied the association between smoking prevalence
in the population and the incidence and mortality of lung cancer
in an ecological analysis. For age-standardized incidence and
mortality rates per 100,000 person-years, the source of regression
analysis was the age-standardized incidence rate of lung cancer in
European countries reported by Ferlay et al. and the prevalence of
smoking prevalence in the population aged≥15 years based on a
WHO report from 1998 to 2002 (7). Significance of correlation
was not calculated; Figure 4 was created to demonstrate the
group of countries which are within and out of the 95% predictive
range. All calculations were performed with R version 3.5.2
(20/12/2018) with package boot version 1.3-20.
RESULTS
Crude Numbers
In 2011, 7,158 new lung cancer cases were registered in the NHIF
database, while in 2016 we found 6,996 new cases resulting in
a crude annual rate of 71.9 to 71.4 per 100,000 person-years
during the 6-year study period. The proportion of male patients
decreased from 63.17% to 59.69% from 2011 to 2016. The mean
age at diagnosis was 64.5 years in men (SD ± 9.85) and 64.9
years in women (SD ± 11.2) in 2011, which increased to 65.8
years (SD ± 9.41) and 66.0 years (SD ± 10.5) (Table 2 and
Supplementary Table 1).
The annual number of patients who died of lung cancer was
between 6,045 (2011) and 6,465 (2016) during the study period
(Table 2 and Supplementary Table 2). The mean age at the time
of death increased from 66.5 (SD ± 10.4) to 68.0 (SD ± 9.68)
years between 2011 and 2016, and was higher among females
during the whole study period (67.2–68.6 years vs. 66.1–67.6
years in males).
Incidence Rates
A continuous and significant decrease was detected in the
incidence rate of lung cancer in men between 2011 and 2016.
In 2011, the age-adjusted incident rate (standard: ESP 2013)
was 115.7/100,000 person-years (95% CI: 112.3–119.1), while
in 2016 it was 101.6/100.000 person-years (95% CI: 98.5–
104.7), resulting in an absolute change of −13,9% (Figure 1, TA
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FIGURE 1 | Age-standardized incidence rates (standard: ESP 2013) of lung cancer by sex in Hungary between 2011 and 2016 (per 100,000 person-years; dotted
lines represent 95% CI). CI, confidence interval.
Supplementary Table 3). On the other hand, incidence rates in
women increased from 48.3 to 50.3 per 100,000 person-years
(95% CI: 46.5–50.2 and 48.5–52.2), showing a mean annual
change of 1.23% (p = 0.028). Consequently, we did not find any
significant change in incidence rates in the whole lung cancer
population during the study period (p = 0.075). When applying
ESP 1976, age-standardized incidence rates were 84.7 (in 2011)
and 72.6 (in 2016) per 100,000 person-years in male lung cancer
patients and 36.9 (in 2011) and 38.0 (in 2016) in female patients
(Supplementary Table 3).
Mortality Rates
The age-standardized mortality rate (standard: ESP 2013) of
lung cancer varied between 103.8 (95% CI: 100.52–107.00)
and 97.2 (95% CI: 94.12–100.25) per 100,000 person-years in
men and between 38.3 (95% CI: 36.6–39.9) and 42.7 (95%
CI: 41.0–44.4) in women (Figure 2). There was no significant
change in age-standardized mortality rates in male patients
from 2011 to 2016, in contrast, age-standardized mortality
rates significantly increased by 2.4% in women (95% CI:
1.7%–3.5%; p = 0.01) (Supplementary Table 3). We did not
find any significant changes in age-standardized mortality
rates in the total patient population (mean annual change:
0.48%; 95% CI: −0.27%–0.94%; p = 0.067). When using
ESP 1976, age-standardized mortality rates were found to
be 72.8–69.7 among males and 27.0–29.3 among females
(Supplementary Table 3).
Using ESP 1976 for standardization calculations to compare
our results to previously reported values for Hungary, the age-
standardized incidence rate per 100,000 person-years in men
was 78.3 and age-standardized mortality was 72.8 in 2012. These
results are different from those reported by Ferlay et al. for
European countries from the same year, 2012 (109.3 and 96.4),
as seen in Figure 3 and Supplementary Table 3. In Figure 3,
a dot shows age-standardized incidence and mortality rates
together for a country. The Y axis represents the standardized
mortality rate per 100,000 population, while the X axis represents
the standardized incidence rate per 100,000 population. Among
women, there was also a considerable difference between our
results based on the NHIF database and the publication by
Ferlay et al.: we found an incidence rate of 35.7 and a
mortality rate of 28.0 in 2012 (Supplementary Table 3), while
those reported by Ferlay et al. were 46.5 and 37.7, respectively
(Supplementary Figure 1).
In the ecological study of age-standardized incidence rates
of European countries in 2012 from Ferlay in relation to
smoking prevalence in 1998–2002 based on WHO data, only
the Hungarian incidence rate was out of the 95% predictive
range as seen in Figure 4. On the other hand, using our results
based on the NHIF database, the Hungarian value fell within
the range. (In Figure 4, incidence rates of lung cancer are
presented as a function of the prevalence of tobacco smoking. The
X axis represents the age-standardized prevalence of smoking
expressed in percentages in the population aged >15 years
between 1998 and 2002 and the Y axis represents the age-
standardized incidence rates of different European countries,
thus merging these data in one dot).
DISCUSSION
Our nationwide, retrospective, longitudinal study provides
comprehensive information on the epidemiology of lung cancer
in Hungary using the database of the NHIF.
The main findings of this large-scale evaluation can be
summarized as follows:
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FIGURE 2 | Age-standardized mortality rates (standard: ESP 2013) of lung cancer by sex in Hungary between 2011 and 2016 (per 100,000 person-years; dotted
lines represent the 95% CI). CI, confidence interval.
FIGURE 3 | Age-standardized incidence and mortality rates per 100,000 person-years among male lung cancer patients in European countries and Hungary based
on the NHIF survey in 2012 (using ESP 1976). Description: A dot in the graph shows age-standardized incidence and mortality rates together for a country. The Y axis
represents the standardized mortality rate per 100,000 population, while the X axis represents the standardized incidence rate per 100,000 population.
1. Hungarian age-standardized incidence and mortality rates of
lung cancer were high but lower than those reported in earlier
publications both among men and women.
2. The age-standardized incidence of lung cancer significantly
decreased in men, while we found a significant increase
among women during the study period.
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FIGURE 4 | Correlation between the age-standardized incidence rate of lung cancer in European countries in 2012 based on the report by Ferlay et al. (2) and the
age-standardized prevalence (%) of tobacco smoking in the population aged ≥15 years in 1998–2002. Description: incidence rates of lung cancer are presented as a
function of the prevalence of tobacco smoking. The X axis represents the age-standardized prevalence of smoking expressed in percentages in the population aged
>15 years between 1998 and 2002 and the Y axis represents the age-standardized incidence rates of different European countries, thus merging these data in
one dot.
The decreasing trend in the incidence of lung cancer in men
is well-documented, which was preceded by a decreasing trend
in smoking starting from the 1950s (8, 9). We found similar
trends in our nationwide NHIF database study where incidence
rates among men significantly decreased from 115.7 to 101.6 per
100,000 person-years between 2011 and 2016, corresponding to a
decrease of 2.35%.
Differences in trends among males vs. females could be
explained by a number of factors including genetic and epigenetic
differences, gender-specific lifestyle behaviors, or differences in
sex hormone activity (10). However, it can be concluded that
the most important risk factor for the development of lung
cancer is smoking in both genders (11, 12). Smoking among
women has significantly increased since the 1960s, resulting
in a consequent increase in the risk of lung cancer in the
female population (13). According to a Hungarian survey on
smoking prevalence published in 2010, 40.6% of males and
31.7% of females smoked regularly or occasionally (14). When
comparing their results to previous local reports, the authors of
this publication found a stagnant trend in smoking among men
and an increasing trend among women. A new anti-smoking
law was launched in Hungary in 2011, and the Methodological
Support Center for Smoking Cessation opened its gates at the
National Korányi Institute of Pulmonology in 2012 to monitor
the efficacy of the new regulation. In their latest report in
2013, they confirmed previous findings on smoking habits in
Hungary: the proportion of male smokers showed a significant
decrease (to 32%), while the prevalence of smoking among
women was stable during the observation period (24–25%) (15).
This changing prevalence of smoking is also in line with our
findings showing a decreasing difference in the risk of lung
cancer incidence and mortality between the two sexes in all
age cohorts.
The mean age at the diagnosis of lung cancer was 64.7 years
in 2011, which increased to 65.9 by the end of the 6-years
study period. The mean age of patients at the time of death
was about 2 years higher than the mean age at diagnosis, and
showed an increasing trend between 2011 and 2016 (from 66.5
to 68.0 years). Our study supports previous findings showing
an increase in the mean age at the time of lung cancer
diagnosis (16).
One of the main findings of our nationwide study is that the
incidence and mortality rates of lung cancer among men and
women were definitely lower than those reported in previous
publications. The most commonly cited source which reported
the highest incidence of lung cancer in Hungary is the article
series by Ferlay et al. (3). These reports used statistical models
to estimate incidence and mortality rates at 25 cancer sites in 40
European countries based on published national cancer registry
data where available, and estimated rates wherever no exact data
were found. Hungary did not report any nationwide incidence
rates during the study period of Ferlay et al., hence the rates
were calculated based on WHOmortality data by approximating
with neighboring countries’ incidence to mortality rate ratio.
Furthermore, while several countries collected incidence and
mortality data from cancer or lung cancer registries, only
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mortality data were available from Hungary based on post-
mortem reports of the CSO. It is important to note that
cancer diagnosis rates are reported to be higher in autopsy
findings compared to clinical findings, therefore autopsy rates
for hospital deaths influence the probability of identifying lung
cancer. A recent study in the Czech Republic, another Central
European country, found a 44% higher incidence of lung cancer
in autopsy reports compared to clinical settings (17). Previous
publications also reported a 11–28% higher incidence of cancer
in autopsy reports than those reported by clinicians (18, 19).
Based on a WHO report, Hungary is one of the countries
with the highest autopsy rates for hospital deaths: dissection
is performed in 36.9% of patients who die at hospitals (20).
On the other hand, some of the countries with the lowest
reported incidence and mortality of lung cancer only have
autopsy rates of 3.2% (Italy), 11.1% (Norway), and 8.4% (Sweden)
(20). Consequently, the methodology applied by Ferlay may have
played an important part in the overestimation of incidence rates
in Hungary.
The article series published in EJC projected lung cancer
incidence and mortality rates to be 109.3 and 96.4 among
men and 46.5 and 37.7 per 100,000 person-years among
women in 2012 using ESP 1976 (2). Incidence and mortality
rates in our study were 78.3 and 72.8 among men and
35.7 and 28.02 among women, respectively (with ESP
1976), corresponding to 28.4–24.5% and 23.2–25.7% higher
differences, which could be relevant when considering the
position of Hungary regarding lung cancer rates among
European countries.
In the European Health Information Gateway report (WHO
Europe), the age-standardized prevalence of smoking among
Hungarian men was found to be lower in the population aged
≥15 years than in several other Eastern European as well as
Balkan countries including Serbia, Romania and Montenegro
(7). Similar differences were seen regarding smoking prevalence
among women: Hungary was not among the highest ranked
countries. Although several other risk factors were identified
for lung cancer (9, 10), smoking is still one of the main risk
factors. Considering this, incidence and mortality rates of lung
cancer may be similar or even lower in Hungary than in these
countries, and not the highest in Europe. This hypothesis is
supported by our analysis of correlation between the incidence
of lung cancer and the prevalence of smoking (as seen in
Figure 4): Hungarian data reported by Ferlay were outside the
95% predictive range, while our results based on the NHIF
database were closer to the correlation trend line, within the 95%
predictive range.
To summarize, relevant differences can be observed between
the present findings and previous reports, which could be
explained by differences in data collection methodology and
the high autopsy rate for hospital deaths in Hungary (20)
leading to a higher incidence of lung cancer diagnosis compared
to countries where incidence data are derived from clinical
registries (1–3).
Our study has certain strengths and limitations. The robust
number of identified lung cancer patients, the carefully cleaned
data, the 6-year-long follow-up period, the nationwide nature
of the NHIF database all provide a solid foundation for
drawing conclusions from our analysis. Nevertheless, the applied
exclusion criteria may have led to the exclusion of patients who
had other cancer types besides lung cancer. However, according
to our estimations, the size of this patient population was not
significant (21). Moreover, the NHIF database does not contain
data on the histological type of lung cancer, on TNM stage,
or the ECOG status of patients, and no laboratory results were
available. Recognizing that mortality and prevalence rates vary
significantly according to TNM stage and histological type,
we did not try to compare our results with findings where
data were stratified according to these parameters. Instead,
we made comparisons with reports that provided overall lung
cancer epidemiology data. In our study, we aimed to highlight
the importance of differences in data collection methodology,
therefore we had to use overall lung cancer incidence and
mortality rates.
In conclusion, our study is the first nationwide investigation
which describes the incidence and mortality rates of lung cancer
in Hungary, showing lower rates than those reported in previous
reports which were typically based on estimations. It should
be emphasized that although the incidence and mortality of
lung cancer are probably lower in Hungary than previously
reported, they are still very high. Our analysis also highlights
the importance of using datasets of similar quality and similar
methodology of estimation for international comparisons. Our
study could also provide guidance on the revision and/or
validation of previous reports on lung cancer in countries where
lung cancer registries were not available.
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